Study on the effect of afatinib maleate tablets combined with cisplatin and paclitaxel in the treatment of advanced non-small cell lung cancer
Niu Sumei
Zhang Chi
Ma Yan
Xu Bin
Duan Wenting
Qian Zhilei
Abstract：Objective To explore the effect of afatinib maleate tablets combined with cisplatin and paclitaxel in the treatment of advanced non-small cell lung cancer.Methods The clinical data of 80 patients with advanced non-small cell lung cancer admitted to the Affiliated Brain Hospital/Chest Hospital of Nanjing Medical University from January 2019 to September 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,with 40 cases in each group.The control group was treated with cisplatin and paclitaxel chemotherapy,and the observation group was treated with afatinib maleate tablets on the basis of the control group.The efficacy,tumor marker level,the quality of life questionnaire-Chinese cancer chemotherapy patients(QLQ-CCC)score,incidence of adverse reactions,and 12-month survival rate were compared between the two groups.Results The disease control rate in the observation group was higher than that in the control group[82.5％(33/40)vs 62.5％(25/40)](x2=4.013,P=0.045).There was no statistically significant difference in objective response rate between the two groups(x2=0.503,P=0.478).After treatment,the average levels of carbohydrate antigen 125,cytokeratin 19 fragment,and carcinoembryonic antigen in the two groups were lower than before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).After treatment,the scores of general feeling,psychological function,social function and physical function of QLQ-CCC in both groups were higher than those before treatment,and those in the observation group were higher than those in the control group(all P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(x2=0.879,P=0.348).The 12-month survival rate of the observation group was higher than that of the control group[62.5％(25/40)vs 40.0％(16/40)](x2=4.053,P=0.044).Conclusion Afatinib maleate tablets combined with cisplatin and paclitaxel in the treatment of advanced non-small cell lung cancer can achieve a good effect,the disease control rate can reach a high level,and can effectively reduce the level of tumor markers,improve the quality of life of patients,and improve the short-term survival rate.
Keywords：Non-small cell lung cancerAfatinibCisplatinPaclitaxel
Publication Date：2024-08-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1160-1163 )